Internal Reference Number: FOI_6308
Date Request Received: 28/09/2021 00:00:00
Date Request Replied To: 16/11/2021 00:00:00
This response was sent via: By Email
Request Summary: usage of anti-VEGF treatments for eye conditions
Request Category: Companies
| Question Number 1: . For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatements: 鈥� Aflibercept 鈥� Bevacizumab 鈥� Brolucizumab 鈥� Dexamethasone 鈥� Fluocinolone acetonide 鈥� Ranibizumab | |
| Answer To Question 1: Aflibercept 689 Bevacizumab 1 Brolucizumab 0 Dexamethasone 16 Fluocinolone acetonide 0 Ranibizumab 33 | |
| Question Number 2: For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy. 鈥� Aflibercept 鈥� Bevacizumab 鈥� Brolucizumab 鈥� Dexamethasone 鈥� Fluocinolone acetonide 鈥� Ranibizumab | |
| Answer To Question 2: Aflibercept 104 Bevacizumab 0 Brolucizumab 0 Dexamethasone 0 Fluocinolone acetonide 0 Ranibizumab 3 | |
| Question Number 3: Within your trust, how many intra-vitreal injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021: 鈥� Aflibercept 鈥� Bevacizumab 鈥� Brolucizumab 鈥� Dexamethasone 鈥� Ranibizumab | |
| Answer To Question 3: Aflibercept 1495 Bevacizumab 2 Brolucizumab 0 Dexamethasone 17 Ranibizumab 75 | |
| Question Number 4: If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY 鈥� Aflibercept 鈥� Bevacizumab 鈥� Brolucizumab 鈥� Dexamethasone 鈥� Ranibizumab | |
| Answer To Question 4: Aflibercept 1034 Bevacizumab 2 Brolucizumab 0 Dexamethasone 0 Ranibizumab 65 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
